DMK Pharmaceuticals Announces Regaining Full Rights to ZIMHI® for Opioid Overdose Treatment

DMK Pharmaceuticals Corporation (Nasdaq: DMK) has recently regained complete commercialization rights for ZIMHI® (naloxone), a product aimed at treating opioid overdose and substance use disorders. The company terminated its exclusive commercialization and distribution agreement with US WorldMeds, LLC, leading to new opportunities for DMK to bring ZIMHI to market in the United States, Canada, and Europe.

DMK is actively seeking commercialization avenues for ZIMHI, with a primary focus on targeting first responders in the United States. The market data indicates a significant and unmet demand in this sector. ZIMHI acts rapidly to restore breathing and prevent death or prolonged hospitalization, making it an ideal product for first responders, especially in cases of fentanyl overdose.

Dr. Eboo Versi, CEO of DMK Pharmaceuticals, expressed enthusiasm about engaging with partners domestically and internationally to drive long-term growth and explore new commercialization pathways. The company aims to expand its business relationships outside the United States while executing an ambitious operating plan within the country, maximizing benefits for patients and stakeholders and delivering optimal shareholder value.

DMK Pharmaceuticals is a neuro-biotech company that focuses on developing and commercializing products for opioid overdose and substance use disorders. The FDA has approved DMK's ZIMHI (naloxone) for opioid overdose treatment. Additionally, DMK is dedicated to developing novel therapies for opioid use disorder and other neuro-based conditions. The company's research includes endorphin-inspired drug design, utilizing mono, bi-, and tri-functional small molecules to regulate critical nervous system networks. With a library of approximately 750 small molecule neuropeptide analogues, DMK aims to address significant unmet medical needs by restoring disrupted physiological balance.

DPI-125, DMK's lead clinical-stage product candidate, is being studied as a potential treatment for opioid use disorder and moderate to severe pain. Other development-stage product candidates include DPI-221 for bladder-control problems and DPI-289 for severe end-stage Parkinson's disease.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those anticipated. The Company acknowledges the importance of obtaining sufficient funding for its operations, satisfying obligations and liabilities, and funding ongoing activities. The availability and amount of such funding cannot be guaranteed. Any unexpected developments or events may impact the Company's ability to fulfill its plans. The Company disclaims any obligation to update forward-looking statements, and readers should not rely solely on them as predictions of future events.